<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2379">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130190</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2021-0741</org_study_id>
    <nct_id>NCT05130190</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation of Adenomyosis</brief_title>
  <official_title>Radiofrequency Ablation of Adenomyosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hologic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the effects of radiofrequency ablation on adenomyosis through the pathological&#xD;
      analysis of treated tissue that has been removed during planned hysterectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative evidence of adenomyoma tissue ablation as assessed by pathological analysis</measure>
    <time_frame>Day of intervention within 4 hours of RF treatment and 2 hours of completion of hysterectomy</time_frame>
    <description>Evidence of ablation to be determined through TTC staining with presence of a pink-maroon color change indicating functional enzyme activity and absence of color change indicating non-functional enzyme activity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Adenomyosis</condition>
  <arm_group>
    <arm_group_label>RF Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>At the time of the subject's trans-abdominal or laparoscopic hysterectomy, the ProVu System will be used to apply RF treatment to one or two adenomas, focal areas of adenomyosis, or diffuse adenomyosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RF Treatment</intervention_name>
    <description>ProVu treatment probe will be energized and RF energy delivered in a pre-programmed, controlled method based on the predetermined size of the affected tissue.</description>
    <arm_group_label>RF Treatment</arm_group_label>
    <other_name>ProVu System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  planning to undergo an abdominal, laparoscopic, or robotic-assisted hysterectomy due&#xD;
             to benign conditions&#xD;
&#xD;
          -  uterus &lt; 16 weeks gestational size if undergoing a laparoscopic or robotic procedure&#xD;
             (no size limit for patients planning to undergo a transabdominal hysterectomy)&#xD;
&#xD;
          -  at least one area of focal or diffuse adenomyosis or adenomyomas that is/are&#xD;
             contralateral to any fibroids as determined by MRI&#xD;
&#xD;
          -  able to provide informed consent&#xD;
&#xD;
          -  suitable candidates for surgery (have passed a standard pre-operative health&#xD;
             assessment)&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  require emergent hysterectomy or vaginal hysterectomy&#xD;
&#xD;
          -  have a uterus &gt; 16 weeks gestational size if undergoing a laparoscopic or robotic&#xD;
             procedure (no size limit for patients planning to undergo a transabdominal&#xD;
             hysterectomy)&#xD;
&#xD;
          -  have fibroids in the proximity of the target adenomyosis (same side, similar location)&#xD;
&#xD;
          -  are not appropriate surgical candidates as determined during pre-operative health&#xD;
             assessment&#xD;
&#xD;
          -  are unable or unwilling to undergo a hysterectomy&#xD;
&#xD;
          -  are pregnant or lactating&#xD;
&#xD;
          -  are under the age of 18 years&#xD;
&#xD;
          -  have active pelvic inflammatory disease&#xD;
&#xD;
          -  have a history of gynecologic malignancy within the past 3 years&#xD;
&#xD;
          -  are unable to give informed consent&#xD;
&#xD;
          -  have an implantable uterine or fallopian tube device for contraception&#xD;
&#xD;
          -  are not English speaking&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Kho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marisa Latham, BSN</last_name>
      <phone>214-762-6221</phone>
      <email>marisa.latham@utsouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Kimberly Kho</investigator_full_name>
    <investigator_title>Associate Professor of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>adenomyosis</keyword>
  <keyword>radiofrequency ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomyosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

